Sir,
Lupus erythematosus (LE) is an autoimmune disorder characterized by attack of an individual's immune system against his or her own healthy tissues, especially nuclear components. Classically, LE can be divided into systemic lupus erythematosus (SLE) and cutaneous or discoid lupus erythematosus (DLE), which is milder and usually affects only the skin, causing a red, raised rash on the face and scalp. About 5%-10% of patients with DLE will progress to SLE. 1 The mucous membranes may be also affected by changes that are clinically similar to those of the skin. Although involvement of the oral cavity is rare, oral manifestations of LE can appear on the mucosa of the gum, palate, and inferior lip, and sometimes these regions are involved simultaneously. 2 The therapeutic approach toward oral LE is still under debate. In practice, patients usually have undergone unsuccessful treatment using nonsteroidal anti-inflammatory drugs and immunosuppressive therapy, as well as radical surgery after neoplastic degeneration. 2 Here, we report the case of a 54-year-old Caucasian woman with a three-year history of oral LE.
She was treated locally with steroids and two sessions of diathermocoagulation, and also received systemic therapy with prednisone. No signs of improvement had been recorded and then no other pharmacological treatments were administered.
She had three distinct lesions on her lower lip and one lesion on the vestibular mucosa of the right cheek, and no other morbidities. She complained of burning pain and difficulty while chewing and phonation (Figure 1 (a), (b)). However the diagnosis was confirmed by incisional biopsy performed two weeks before our treatment.
After administering local anesthesia (2% mepivacaine plus epinephrine and bicarbonate), we treated the patient using a CO 2 laser equipped with a 5 Â 5 mm scanner at 5 W/cm 2 of power. The treatment was repeated 30 days later. The lesions resolved and the patient was seen monthly for follow-up evaluation. At 24 months, the patient remained free of oral lesions, confirming successful control using CO 2 laser vaporization ( Figure 1(c), (d) ).
Discussion
Oral mucosal involvement is seen in 9%-45% of patients with SLE and in 3%-20% of patients with DLE. 1, 3, 4 Because the oral lesions of LE do not respond to conventional pharmacologic treatments for LE, treatment usually consists of diathermocoagulation or surgical excision. 4 The CO 2 laser emits light in the near infrared region at 10.600 nm, which is absorbed by tissue water. The laser-tissue interaction heats cells instantly to more than 100 C, resulting in: vaporization of superficial tissue layers, coagulation and necrosis of cells, denaturation of matrix proteins and non-fatal damage in a deeper zone. CO 2 laser is usually indicated to treat several cutaneous diseases such as benign tumors (keratosis, warts, dermic or verrucosus nevus) or aesthetic defects as skin aging and wrinkles.
Following the principle of selective photothermolysis, this laser allows to the surgeon to achieve optimal precision during the treatment, and by also reducing the thermal damage of surrounding tissues, as happens in DTC diathermocoagulation, the healing process starts immediately. 5 Zhao et al. reported on the effects of CO 2 laser irradiation of the oral mucosa, and emphasized the speed of healing after surgery. 6 They also did not observe any inflammation during the healing process. They postulated that the absence of inflammation was due to the sealing of small blood and lymphatic vessels, which reduced the release of inflammatory mediators. 6 We therefore decided to use CO 2 laser surgery because it would reduce our patient's discomfort during the rapid healing process. Although clinical healing was observed after the first treatment, we decided to repeat the procedure because a limitation of this technique is the difficulty in determining the depth of epithelial tissue, and we wanted to ensure adequate treatment. To the best of our knowledge, this is the first report of a patient with oral LE lesions successfully treated using CO 2 laser surgery.
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